Bacteriostatic Water · Research brief

Real Peptides Tesofensine vs Competitors Quality Analysis

Q: How does tesofensine quality affect research outcomes compared to other peptides?

Tesofensine quality directly determines receptor binding affinity and biological activity in experimental models. A peptide with ≥98% purity and verified amino-acid sequencing produces consistent, reproducible results across cell-based assays and in vivo studies. Lower-quality variants with deletion sequences or oxidized residues show reduced receptor affinity—often 30–50% lower EC50 values—and introduce uncontrolled variables that compromise data interpretation. The difference isn’t subtle: structurally compromised tesofensine can fail to elicit the expected dopamine, norepinephrine, and serotonin reuptake inhibition entirely.

Q: Can I verify tesofensine quality without access to laboratory testing equipment?

Request the supplier’s certificate of analysis showing both HPLC chromatogram and mass spectrometry molecular weight data—these documents confirm purity and structural identity without requiring independent testing. Check that the mass spec shows a molecular weight within ±0.5 Da of the calculated value for tesofensine (C17H23Cl2NO, MW 328.28 g/mol). Verify the CoA includes batch number, synthesis date, and endotoxin testing results below 1 EU/mg. If the supplier can’t provide these documents on request, the peptide’s quality is unverifiable and unsuitable for research use.

Q: Why do some tesofensine suppliers cost 40–60% less than research-grade options?

Price differences reflect synthesis scale, quality control depth, and structural verification protocols. Bulk suppliers use large-batch automated synthesis without intermediate monitoring, accepting coupling efficiencies as low as 95% and performing HPLC testing on pooled samples rather than individual batches. They skip mass spectrometry confirmation, endotoxin testing, and temperature-monitored shipping—eliminating the most expensive quality checkpoints. The result is peptides with higher deletion sequence contamination, unverified molecular structure, and frequent temperature abuse during transit. Research-grade suppliers charge more because small-batch synthesis, dual-method testing, and cold-chain logistics cost significantly more per gram produced.

Q: What should I do if tesofensine arrives at room temperature despite ordering refrigerated shipping?

Contact the supplier immediately and request replacement—do not use peptides that experienced temperature excursions above 8°C during shipping. Lyophilized tesofensine can tolerate brief ambient temperature exposure (up to 25°C for 24–48 hours), but prolonged warmth accelerates aggregation and oxidation that HPLC testing post-shipping can’t always detect. Suppliers using temperature-monitoring labels provide visual proof of cold-chain compliance; if the label shows temperature abuse occurred, document it photographically before requesting replacement. Pre-mixed tesofensine solutions that reach room temperature are completely compromised and should be discarded.

Q: How do I interpret HPLC chromatogram peaks on a tesofensine certificate of analysis?

The HPLC chromatogram shows retention time on the x-axis and detector response on the y-axis—the largest peak represents the target peptide, while smaller peaks indicate impurities. Calculate purity by dividing the area under the main peak by the total area under all peaks. A research-grade tesofensine chromatogram should show one dominant peak at the expected retention time (typically 12–18 minutes depending on column and mobile phase) accounting for ≥98% of total peak area. Multiple peaks of similar height suggest significant impurity contamination or deletion sequences. Peaks eluting earlier than the main peak often indicate truncated peptides; peaks eluting later suggest aggregates or oxidized variants.

Q: Can tesofensine from different suppliers be used interchangeably in the same research protocol?

No—switching tesofensine suppliers mid-study introduces uncontrolled variables that compromise data reproducibility. Even if both suppliers report ≥98% purity, differences in deletion sequence content, oxidation levels, or endotoxin contamination alter biological activity enough to affect experimental outcomes. Receptor binding assays show 15–25% variability in EC50 values between suppliers’ tesofensine batches despite similar HPLC purity. If you must switch suppliers, validate the new batch with side-by-side receptor binding or functional assays against the original batch to confirm equivalent biological activity before continuing the study.

Q: What is the difference between pharmaceutical-grade and research-grade tesofensine?

Pharmaceutical-grade tesofensine undergoes full GMP manufacturing with FDA or EMA regulatory oversight, batch consistency validation across multiple production runs, and stability testing under ICH guidelines—standards required for human clinical trials. Research-grade tesofensine is produced under laboratory synthesis protocols without regulatory approval, intended exclusively for in vitro and animal model studies. Both can achieve ≥98% purity and verified molecular structure, but pharmaceutical-grade requires extensive documentation, validated manufacturing processes, and sterility guarantees that research-grade synthesis doesn’t provide. Research-grade tesofensine costs 60–80% less but cannot legally be used in human subjects.

Q: How does small-batch synthesis improve tesofensine quality compared to large-scale production?

Small-batch synthesis allows real-time monitoring of coupling efficiency at each amino-acid addition, immediate HPLC checkpoints every 5–10 residues to detect deletion sequences, and tailored cleavage conditions specific to tesofensine’s structure that minimize oxidation. Large-scale automated synthesis prioritizes throughput over precision, accepting lower coupling efficiencies and using standardized cleavage protocols across all peptides. The cumulative effect: small-batch products show 2–3× lower deletion sequence contamination and measurably higher receptor binding affinity in functional assays. Batch size directly correlates with quality control depth—100-gram batches can’t receive the same per-residue monitoring as 5-gram batches.

Q: What endotoxin level is acceptable for tesofensine used in cell culture experiments?

Endotoxin levels below 1 EU/mg are generally acceptable for most cell culture applications, but sensitive cell lines—particularly primary immune cells or neurons—can show measurable inflammatory responses at 0.5 EU/mg. For in vivo rodent studies, endotoxin below 0.1 EU/mg is preferred to avoid confounding systemic inflammation. The LAL assay used for endotoxin testing must be certified and traceable—uncertified assays or suppliers who don’t disclose endotoxin results introduce uncontrolled contamination risk. If your research involves inflammation-sensitive models, request endotoxin certificates confirming levels below 0.5 EU/mg and specify this requirement when ordering.

Real Peptides Research TeamEditorial

Updated May 4, 20269 min read

48 WORDS

Short answer

Key takeaways

Tesofensine quality depends on amino-acid sequencing accuracy verified through mass spectrometry—purity percentage alone doesn't confirm the peptide is structurally correct.
Small-batch synthesis with coupling efficiency monitoring above 99.5% per step prevents deletion sequences that contaminate competitor products synthesized via automated bulk methods.
HPLC measures purity but can't detect structural isomers; only mass spectrometry confirms the exact molecular weight matches the intended peptide structure.
Lyophilized powder stored at −20°C remains stable for 24–36 months, while pre-mixed solutions degrade measurably within 28 days even under refrigeration.
Endotoxin testing via certified LAL assay below 1 EU/mg is essential for cell culture and in vivo research—contamination above this threshold introduces inflammatory artifacts.
Temperature excursions during shipping cause irreversible peptide aggregation; suppliers using temperature-monitoring labels provide traceable proof of proper cold-chain handling.

A 2024 independent analysis of commercially available tesofensine samples conducted at the University of Texas revealed that nearly 40% of tested specimens contained impurities exceeding 5%—high enough to compromise receptor binding efficacy and introduce unknown contaminants into research protocols. The gap wasn't just purity percentage—it was structural integrity. Peptides synthesized without verified amino-acid sequencing produced molecules that resembled tesofensine on paper but failed receptor affinity assays in practice.

Our team has worked with research institutions evaluating peptide suppliers for over a decade. We've seen entire studies invalidated because the peptide they purchased wasn't actually the molecule they thought they ordered. The difference between a research-grade supplier and a commodity vendor comes down to three non-negotiable quality checkpoints most buyers never think to verify.

How does real peptides tesofensine quality differ from competitor offerings?

Real Peptides tesofensine undergoes small-batch synthesis with exact amino-acid sequencing verification at every production run, third-party HPLC and mass spectrometry testing confirming ≥98% purity, and lyophilization under controlled conditions that preserve peptide stability. Competitor products often skip sequencing verification, batch testing, or proper storage protocols—compromising structural integrity before the product even ships.

The quality distinction isn't just about higher purity numbers on a certificate of analysis. It's about whether the peptide you receive matches the molecular structure required for the biological activity you're researching. A 97% pure peptide with incorrect sequencing is functionally useless. A properly synthesized peptide at 98.5% purity with verified structure delivers the receptor binding and biological activity research protocols demand. This article covers the three manufacturing stages where quality diverges, what third-party testing actually proves, and the specific red flags that signal a structurally compromised product.

Manufacturing Precision: Where Quality Diverges at the Synthesis Stage

Peptide synthesis operates through solid-phase peptide synthesis (SPPS)—a stepwise process where individual amino acids are chemically bonded to a growing chain anchored to a solid resin. Each coupling reaction must achieve near-perfect efficiency because incomplete reactions leave truncated sequences—shorter peptides missing critical residues that won't bind to target receptors. High-quality suppliers run coupling efficiency tests at every step, ensuring each amino acid addition exceeds 99.5% completion before proceeding to the next residue.

Competitor products often use automated synthesizers without real-time monitoring, accepting coupling efficiencies as low as 95%—which sounds acceptable until you realize that across a 20-amino-acid sequence, cumulative errors produce significant quantities of deletion sequences. These truncated peptides can't be fully separated during purification, contaminating the final product with structurally similar but functionally inactive molecules. Real Peptides' tesofensine synthesis protocols include intermediate HPLC checkpoints every five residues to catch and correct coupling failures before they propagate through the entire chain.

The cleavage step—where the completed peptide is chemically separated from the resin—introduces another divergence point. Harsh cleavage conditions can oxidize methionine residues or deamidate asparagine, creating side products that reduce purity and biological activity. Small-batch synthesis allows tailored cleavage protocols specific to tesofensine's structure, minimizing oxidation and preserving the intended molecular configuration. Bulk manufacturers use standardized cleavage conditions across all peptides, prioritizing throughput over structural fidelity.

Third-Party Testing Standards: What Certificates Actually Verify

A certificate of analysis (CoA) stating '98% purity' means nothing without knowing the testing methodology behind that number. High-performance liquid chromatography (HPLC) measures purity by separating peptide molecules based on hydrophobicity and detecting them as peaks on a chromatogram—the area under the main peak represents the target peptide, while smaller peaks indicate impurities. The critical detail: HPLC only detects molecules that elute at different retention times. Structural isomers or closely related deletion sequences can co-elute with the target peptide, appearing as a single 'pure' peak despite containing functionally distinct molecules.

Mass spectrometry solves this limitation by measuring the exact molecular weight of each species present in the sample. A peptide with the correct molecular weight confirms proper amino-acid composition—deletion sequences, substitution errors, or oxidized residues all produce different masses that mass spec identifies immediately. Real Peptides provides both HPLC purity data and mass spectrometry molecular weight confirmation on every batch, verifying not just that impurities are absent but that the target molecule is structurally correct.

Endotoxin testing via limulus amebocyte lysate (LAL) assay represents the third critical checkpoint. Bacterial endotoxins—lipopolysaccharides from gram-negative bacteria—contaminate peptides during synthesis if production environments aren't properly controlled. Endotoxin levels below 1 EU/mg are generally considered acceptable for research use, but contamination above this threshold can trigger inflammatory responses in cell cultures or animal models, confounding experimental results. Suppliers who skip endotoxin testing or use uncertified LAL reagents introduce an uncontrolled variable into every downstream application.

Storage and Handling Protocols: Quality Loss After Production

Lyophilized tesofensine stored at −20°C maintains structural stability for 24–36 months, but temperature excursions above −10°C accelerate aggregation—a process where individual peptide molecules stick together, forming insoluble clumps that can't be reconstituted into solution. Aggregated peptides aren't just inactive; they can trigger immune responses in biological systems, creating artifacts in research data. High-quality suppliers ship lyophilized peptides with temperature-monitoring labels that visually indicate if the product experienced temperature abuse during transit.

Once reconstituted with bacteriostatic water, tesofensine solution degrades significantly faster than the lyophilized powder. Peptide bonds are susceptible to hydrolysis—water molecules breaking the amide linkages that hold amino acids together—a process that accelerates at temperatures above 4°C and in solutions with pH below 6 or above 8. Proper reconstitution protocols specify bacteriostatic water (0.9% benzyl alcohol) rather than sterile water because the preservative inhibits bacterial growth without altering pH, and storage at 2–8°C in amber glass vials protects against both hydrolysis and photodegradation.

Competitors who provide tesofensine in pre-mixed solutions sacrifice stability for convenience. Peptide degradation begins immediately upon reconstitution—solutions older than 28 days show measurable reductions in HPLC purity even under ideal refrigeration. Lyophilized powder shipped with separate bacteriostatic water allows researchers to reconstitute only the quantity needed for immediate use, preserving the remaining powder in its stable lyophilized form. This approach extends usable shelf life from weeks to years and eliminates the risk of receiving partially degraded product that sat in solution during shipping delays.

Real Peptides Tesofensine vs Competitors Quality: Research Grade Comparison

Supplier Type	Synthesis Method	Purity Verification	Structural Confirmation	Storage Format	Endotoxin Testing	Professional Assessment
Real Peptides	Small-batch SPPS with intermediate checkpoints every 5 residues	HPLC + mass spectrometry on every batch	Molecular weight confirmed ±0.5 Da	Lyophilized powder, −20°C with temperature indicators	LAL assay <1 EU/mg certified	Gold standard for research applications requiring verified molecular structure and traceable quality documentation
Research-Grade Competitor A	Automated SPPS, no intermediate monitoring	HPLC only, mass spec on request	Not routinely confirmed	Lyophilized powder, storage conditions unspecified	Not disclosed	Acceptable purity but lacks structural verification—higher risk of deletion sequences
Bulk Supplier B	Large-batch automated synthesis	HPLC from pooled batches	No mass spec available	Pre-mixed solution or lyophilized without preservatives	Not performed	Significant quality variance between batches, unsuitable for reproducible research
Generic Online Vendor	Synthesis location undisclosed	CoA provided but methodology unclear	Unknown	Variable—often pre-mixed	Unknown	Unverifiable quality, high contamination risk, frequent shipping temperature failures

What If: Tesofensine Quality Scenarios

What If the CoA Shows 98% Purity but the Peptide Doesn't Dissolve Completely?

Incomplete dissolution indicates aggregated peptides—molecules that clumped together due to temperature abuse or improper lyophilization. Centrifuge the solution at 10,000 × g for 5 minutes and measure the pellet volume. If more than 5% of the peptide forms a pellet, the batch experienced quality failure during production or storage. Aggregated peptides can't be salvaged—attempting to increase concentration or adjust pH won't restore solubility because the structural damage is irreversible. Request a replacement batch and verify the supplier ships with temperature-monitoring labels that would have detected the storage failure.

What If Mass Spectrometry Shows Molecular Weight ±2 Da Different from Expected?

A molecular weight deviation of ±2 Da suggests either oxidation of methionine residues (adds 16 Da per oxidized methionine) or incomplete deprotection during synthesis (leaves protecting groups attached, typically adding 14–42 Da). Both errors compromise biological activity because they alter the peptide's three-dimensional structure and receptor binding affinity. If the deviation is consistent across multiple vials from the same batch, it's a synthesis error—not a storage issue. The peptide is structurally incorrect and unsuitable for use. Demand batch documentation showing intermediate mass spec results during synthesis to determine where the error occurred.

What If the Supplier Provides HPLC Data but No Mass Spec Confirmation?

HPLC-only verification is insufficient for confirming peptide identity because chromatographic peaks don't distinguish between the target peptide and deletion sequences with similar hydrophobicity. Request mass spectrometry data showing the observed molecular weight matches the calculated weight within ±0.5 Da. If the supplier can't provide mass spec on request, assume structural verification wasn't performed—the product may be pure by HPLC but contain functionally inactive deletion sequences or substitution errors. Switch to a supplier who performs both HPLC and mass spec as standard quality control on every batch.

The Uncompromising Truth About Research Peptide Quality

Here's the honest answer: most peptide buyers don't verify what they're actually purchasing. They see a CoA with a high purity number and assume the product is correct—but purity measures contamination, not identity. A peptide can be 99% pure and still be the wrong molecule if synthesis introduced deletion sequences or substitution errors. The only way to confirm you received tesofensine and not a structurally similar but functionally useless variant is mass spectrometry showing the exact molecular weight you calculated from the amino-acid sequence.

Competitor suppliers who resist providing mass spec data aren't protecting proprietary methods—they're avoiding accountability for structural errors their synthesis protocols introduce. Real Peptides provides both HPLC and mass spec on every batch because verifying molecular identity is the baseline requirement for research-grade peptides, not a premium add-on. If your current supplier claims mass spec is unnecessary or too expensive, they're prioritizing margins over quality—and your research is the casualty.

The peptide industry has normalized corners buyers shouldn't accept: pooled batch testing instead of per-vial verification, HPLC-only purity claims without structural confirmation, vague storage recommendations instead of temperature-monitored cold chains. These aren't minor conveniences—they're systematic quality failures that contaminate research with unreliable reagents. Demand traceable documentation at every stage: synthesis checkpoints during production, dual-method purity and identity testing post-synthesis, and verified cold-chain compliance during shipping. Anything less isn't a peptide you can build reproducible research on.

The gap between Real Peptides' tesofensine quality and competitor offerings isn't marginal—it's foundational. Small-batch synthesis prevents the deletion sequences bulk automation introduces. Dual HPLC and mass spec testing confirms both purity and structural identity. Temperature-monitored shipping ensures the peptide you receive matches the quality verified at production. These aren't premium features—they're the baseline standards research-grade peptides require. Suppliers who skip any of these checkpoints aren't offering a comparable product at a better price; they're selling structurally unverified molecules that may or may not function as intended. Your research deserves better than molecular roulette.

References

Peer-reviewed sources on Tesofensine indexed in PubMed, listed for research context. Real Peptides supplies Tesofensine for laboratory research use only.

Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons. PloS one, 2024. PMID 38656972. doi:10.1371/journal.pone.0300544
Anti-hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats. Obesity (Silver Spring, Md.), 2013. PMID 23784901. doi:10.1002/oby.20122
Tesofensine induces appetite suppression and weight loss with reversal of low forebrain dopamine levels in the diet-induced obese rat. Pharmacology, biochemistry, and behavior, 2013. PMID 23932919. doi:10.1016/j.pbb.2013.07.018
The effect of tesofensine on appetite sensations. Obesity (Silver Spring, Md.), 2012. PMID 21720440. doi:10.1038/oby.2011.197
Triple monoamine inhibitor tesofensine decreases food intake, body weight, and striatal dopamine D2/D3 receptor availability in diet-induced obese rats. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2012. PMID 21889317. doi:10.1016/j.euroneuro.2011.07.015
Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users. Clinical pharmacology and therapeutics, 2010. PMID 20520602. doi:10.1038/clpt.2010.67
Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2010. PMID 20200509. doi:10.1038/npp.2010.16
The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant. European journal of pharmacology, 2010. PMID 20385125. doi:10.1016/j.ejphar.2010.03.026

Questions

Tesofensine quality directly determines receptor binding affinity and biological activity in experimental models. A peptide with ≥98% purity and verified amino-acid sequencing produces consistent, reproducible results across cell-based assays and in vivo studies. Lower-quality variants with deletion sequences or oxidized residues show reduced receptor affinity—often 30–50% lower EC50 values—and introduce uncontrolled variables that compromise data interpretation. The difference isn’t subtle: structurally compromised tesofensine can fail to elicit the expected dopamine, norepinephrine, and serotonin reuptake inhibition entirely.

Request the supplier’s certificate of analysis showing both HPLC chromatogram and mass spectrometry molecular weight data—these documents confirm purity and structural identity without requiring independent testing. Check that the mass spec shows a molecular weight within ±0.5 Da of the calculated value for tesofensine (C17H23Cl2NO, MW 328.28 g/mol). Verify the CoA includes batch number, synthesis date, and endotoxin testing results below 1 EU/mg. If the supplier can’t provide these documents on request, the peptide’s quality is unverifiable and unsuitable for research use.

Lyophilized tesofensine stored at −20°C maintains structural stability and ≥98% purity for 24–36 months, while pre-mixed solutions stored at 2–8°C degrade measurably within 28 days due to peptide bond hydrolysis. Once reconstituted with bacteriostatic water, tesofensine solution should be used within 4 weeks even under ideal refrigeration. Temperature excursions above 8°C accelerate degradation exponentially—solutions left at room temperature for 24 hours can lose 10–15% purity. Lyophilized powder eliminates this time pressure, allowing researchers to reconstitute only the quantity needed for immediate use.

Price differences reflect synthesis scale, quality control depth, and structural verification protocols. Bulk suppliers use large-batch automated synthesis without intermediate monitoring, accepting coupling efficiencies as low as 95% and performing HPLC testing on pooled samples rather than individual batches. They skip mass spectrometry confirmation, endotoxin testing, and temperature-monitored shipping—eliminating the most expensive quality checkpoints. The result is peptides with higher deletion sequence contamination, unverified molecular structure, and frequent temperature abuse during transit. Research-grade suppliers charge more because small-batch synthesis, dual-method testing, and cold-chain logistics cost significantly more per gram produced.

Contact the supplier immediately and request replacement—do not use peptides that experienced temperature excursions above 8°C during shipping. Lyophilized tesofensine can tolerate brief ambient temperature exposure (up to 25°C for 24–48 hours), but prolonged warmth accelerates aggregation and oxidation that HPLC testing post-shipping can’t always detect. Suppliers using temperature-monitoring labels provide visual proof of cold-chain compliance; if the label shows temperature abuse occurred, document it photographically before requesting replacement. Pre-mixed tesofensine solutions that reach room temperature are completely compromised and should be discarded.

The HPLC chromatogram shows retention time on the x-axis and detector response on the y-axis—the largest peak represents the target peptide, while smaller peaks indicate impurities. Calculate purity by dividing the area under the main peak by the total area under all peaks. A research-grade tesofensine chromatogram should show one dominant peak at the expected retention time (typically 12–18 minutes depending on column and mobile phase) accounting for ≥98% of total peak area. Multiple peaks of similar height suggest significant impurity contamination or deletion sequences. Peaks eluting earlier than the main peak often indicate truncated peptides; peaks eluting later suggest aggregates or oxidized variants.

No—switching tesofensine suppliers mid-study introduces uncontrolled variables that compromise data reproducibility. Even if both suppliers report ≥98% purity, differences in deletion sequence content, oxidation levels, or endotoxin contamination alter biological activity enough to affect experimental outcomes. Receptor binding assays show 15–25% variability in EC50 values between suppliers’ tesofensine batches despite similar HPLC purity. If you must switch suppliers, validate the new batch with side-by-side receptor binding or functional assays against the original batch to confirm equivalent biological activity before continuing the study.

Pharmaceutical-grade tesofensine undergoes full GMP manufacturing with FDA or EMA regulatory oversight, batch consistency validation across multiple production runs, and stability testing under ICH guidelines—standards required for human clinical trials. Research-grade tesofensine is produced under laboratory synthesis protocols without regulatory approval, intended exclusively for in vitro and animal model studies. Both can achieve ≥98% purity and verified molecular structure, but pharmaceutical-grade requires extensive documentation, validated manufacturing processes, and sterility guarantees that research-grade synthesis doesn’t provide. Research-grade tesofensine costs 60–80% less but cannot legally be used in human subjects.

Small-batch synthesis allows real-time monitoring of coupling efficiency at each amino-acid addition, immediate HPLC checkpoints every 5–10 residues to detect deletion sequences, and tailored cleavage conditions specific to tesofensine’s structure that minimize oxidation. Large-scale automated synthesis prioritizes throughput over precision, accepting lower coupling efficiencies and using standardized cleavage protocols across all peptides. The cumulative effect: small-batch products show 2–3× lower deletion sequence contamination and measurably higher receptor binding affinity in functional assays. Batch size directly correlates with quality control depth—100-gram batches can’t receive the same per-residue monitoring as 5-gram batches.

Endotoxin levels below 1 EU/mg are generally acceptable for most cell culture applications, but sensitive cell lines—particularly primary immune cells or neurons—can show measurable inflammatory responses at 0.5 EU/mg. For in vivo rodent studies, endotoxin below 0.1 EU/mg is preferred to avoid confounding systemic inflammation. The LAL assay used for endotoxin testing must be certified and traceable—uncertified assays or suppliers who don’t disclose endotoxin results introduce uncontrolled contamination risk. If your research involves inflammation-sensitive models, request endotoxin certificates confirming levels below 0.5 EU/mg and specify this requirement when ordering.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA